SCHEMBL1401439

SCHEMBL1401439

N=C(N)NCCC[C@H](N)C(=O)OC(=O)[C@@H](N)Cc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 2/20 0.47
RNPEP Q9H4A4 1/20 0.47
DNPEP Q9ULA0 1/20 0.47
ALPI P09923 1/20 0.44
PKM P14618 1/20 0.44
PTGS1 P23219 1/20 0.44
XIAP P98170 1/20 0.44
SLC7A5 Q01650 1/20 0.44
NPY4R P50391 7/20 0.44
NPY1R P25929 5/20 0.44
MMP2 P08253 1/20 0.43
NPY2R P49146 4/20 0.42
NPY5R Q15761 4/20 0.42
DPP8 Q6V1X1 1/20 0.41
DPP7 Q9UHL4 1/20 0.41
LTA4H P09960 1/20 0.41
LAP3 P28838 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1537375 1.00 ANPEP (0.47) ANPEPRNPEPDNPEPALPIPKM
SCHEMBL27757792 0.90 ANPEP (0.49) ANPEPRNPEPDNPEPALPIPKM
SCHEMBL5320701 0.89 NPY4R (0.55) SLC7A5NPY4RNPY1RNPY2RNPY5R
SCHEMBL7416583 0.86 MMP2 (0.47) ANPEPRNPEPDNPEPALPIPKM
SCHEMBL17164597 0.86 DPP8 (0.40) ANPEPRNPEPDNPEPNPY4RNPY1R
Phenylalanine SCHEMBL17962430 0.86 SLC7A5 (0.50) ANPEPRNPEPDNPEPALPIPKM
Arginine SCHEMBL1537371 0.86 SLC7A5 (0.59) ANPEPRNPEPDNPEPALPIPKM
Arginine SCHEMBL14861498 0.86 SLC7A5 (0.59) ANPEPRNPEPDNPEPALPIPKM
Arginine SCHEMBL2776813 0.86 SLC7A5 (0.59) ANPEPRNPEPDNPEPALPIPKM
Arginine SCHEMBL385198 0.86 SLC7A5 (0.59) ANPEPRNPEPDNPEPALPIPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240191260-A1 METHODS OF PREPARING STABLE NUCLEIC ACID LIQUID FORMULATIONS UNIVERSITY OF NORTH CAROLINA AT WILMINGTON (US) 2024-06-13 US claimed
WO-2024124258-A2 METHODS OF PREPARING STABLE NUCLEIC ACID LIQUID FORMULATIONS UNIVERSITY OF NORTH CAROLINA AT WILMINGTON (US) 2024-06-13 WO claimed
CN-109134371-B Fluorescence ratio probe, synthetic method thereof and application of fluorescence ratio probe in detecting intracellular lysosome formaldehyde 东北大学 2020-07-10 CN claimed
CN-106537145-A Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment 麦特博隆股份有限公司 2017-03-22 CN claimed
US-20080261232-A1 Use of Precursors of Enkephalins and/or Their Fragments in Medical Diagnostics B.R.A.H.M.S AKTIENGESELLSCHAFT (DE) 2008-10-23 US claimed
EP-1745297-A1 USE OF PRECURSORS OF ENKEPHALINS AND/OR THEIR FRAGMENTS IN MEDICAL DIAGNOSTICS SphingoTec GmbH (DE) 2007-01-24 EP claimed
WO-2005114222-A1 USE OF PRECURSORS OF ENKEPHALINS AND/OR THEIR FRAGMENTS IN MEDICAL DIAGNOSTICS SPHINGO TEC GMBH (DE) 2005-12-01 WO claimed
EP-0937139-A4 AMIDASE DIVERSA CORP (US) 2000-08-02 EP claimed
EP-0937139-A1 AMIDASE DIVERSA CORPORATION (US) 1999-08-25 EP claimed
WO-1997048794-A1 AMIDASE RECOMBINANT BIOCATALYSIS, INC. (US) 1997-12-24 WO claimed
US-20240191260-A1 METHODS OF PREPARING STABLE NUCLEIC ACID LIQUID FORMULATIONS UNIVERSITY OF NORTH CAROLINA AT WILMINGTON (US) 2024-06-13 US disclosed
WO-2024124258-A2 METHODS OF PREPARING STABLE NUCLEIC ACID LIQUID FORMULATIONS UNIVERSITY OF NORTH CAROLINA AT WILMINGTON (US) 2024-06-13 WO disclosed
CN-115125283-A Method for screening quorum sensing inhibitor and determining action target point of quorum sensing inhibitor 西北大学 2022-09-30 CN disclosed
US-11117856-B2 Polyamine compounds targeting the efflux pumps of multi-drug resistant bacterial pathogens and methods of using the same UNIVERSITY OF SOUTH FLORIDA (US) 2021-09-14 US disclosed
CN-109134371-B Fluorescence ratio probe, synthetic method thereof and application of fluorescence ratio probe in detecting intracellular lysosome formaldehyde 东北大学 2020-07-10 CN disclosed
CN-1377407-A Transformant producing secondary metabolite modified with functional group and novel biosynthesis genes MEIJI SEIKA CO (JP) 2002-10-30 CN disclosed
WO-1999058640-A2 MCT-1, A HUMAN ONCOGENE PHILADELPHIA HEALTH AND EDUCATION CORPORATION (US) 1999-11-18 WO disclosed
EP-0036420-B1 PEPTIDES HAVING IMUNOSTIMULATING PROPERTIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM INSTITUT PASTEUR (FR) 1983-08-10 EP disclosed
EP-0036420-A1 PEPTIDES HAVING IMUNOSTIMULATING PROPERTIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. PASTEUR INSTITUT (FR) 1981-09-30 EP disclosed
WO-1981000847-A1 PEPTIDES HAVING IMUNOSTIMULATING PROPERTIES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PASTEUR INSTITUT (FR) 1981-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11117856-B2 Polyamine compounds targeting the efflux pumps of multi-drug resistant bacterial pathogens and methods of using the same ABCB11, ABCC1, ABCB1 ANPEP 672/4885RNPEP 594/4885DNPEP 253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.